Demand for anti-superbug remedies boosts sales outlook at Teva supplier Venus Remedies; Recipharm grabs manufacturing deal from Astimex Pharma;

> Peru's tougher GMP requirements on drugmakers have stymied the approval of new drugs in the country. Article

> Venus Remedies, an India-based supplier of meds for Teva Pharmaceutical Industries ($TEVA), expects 15% growth in sales over the next two years in part because of demand for anti-bacterial drugs against superbugs. Report

> Recipharm sealed a development manufacturing deal with Astimex Pharma. Item

> Under a deal announced Monday, Ark Therapeutics Group will manufacture and provide Lymfactin to Laurantis Pharma. Report

Suggested Articles

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

Boehringer Ingelheim is investing $50 million in an animal health plant in Puerto Rico, adding 105 jobs.

Teva will begin producing chemo drug vincristine in the U.S. but has resisted the idea that its withdrawal from the market led to a shortage.